G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US
Shots:
- On Feb 12- 2021- the US FDA has approved Cosela to decrease the incidence of CT induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC
- The launch is supported by the “One Patient Support Program” which is designed to provide access and affordability solutions to eligible patients
- Cosela is the 1st therapy designed to help protect bone marrow (myeloprotection) when administered before treatment with CT
Ref: GlobeNewswire | Image: BioSpace
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com